Genomed Spólka Akcyjna's latest marketcap:
As of 08/31/2026, Genomed Spólka Akcyjna's market capitalization has reached $10.57 M. According to our data, Genomed Spólka Akcyjna is the 42238th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.57 M |
| Revenue (ttm) | 8.22 M |
| Net Income (ttm) | 940,872.42 |
| Shares Out | 1.32 M |
| EPS (ttm) | 0.71 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 07/06/2026 |
| Earnings Date | 08/13/2026 |
Genomed Spólka Akcyjna's yearly market capitalization.
| Date | Market Cap(zł) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/31/2026 | zł39.37 M | $10.57 M | 23.14% | 42238 |
| 12/29/2025 | zł31.98 M | $8.78 M | -9.02% | 38785 |
| 12/30/2024 | zł35.15 M | $8.49 M | -10.74% | 38767 |
| 12/29/2023 | zł39.37 M | $9.98 M | -12.35% | 37117 |
| 12/30/2022 | zł44.92 M | $10.23 M | -0.58% | 35847 |
| 12/30/2021 | zł45.19 M | $11.18 M | 3.64% | 35151 |
| 12/30/2020 | zł43.6 M | $11.67 M | 20.44% | 31602 |
| 12/30/2019 | zł36.2 M | $9.5 M | 7.87% | 29039 |
| 12/21/2018 | zł33.56 M | $8.96 M | 34.39% | 28198 |
| 12/29/2017 | zł24.97 M | $7.16 M | -1.25% | 28404 |
Company Profile
About Genomed Spólka Akcyjna
Genomed Spólka Akcyjna is a leading provider of DNA analysis and congenital disease diagnostic services in Poland. The company specializes in molecular diagnostics, leveraging advanced DNA sequencing technologies for preventive and therapeutic applications, including gene therapy.
Core Services
- DNA Sequencing & Diagnostics: Analysis of mutations linked to congenital diseases across approximately 6,500 genes using next-generation sequencing (NGS) technology.
- Comprehensive DNA Analysis: Includes polymorphism analysis, sequencing of phage genetic material, and bacterial/yeast genome sequencing.
- Genetic Counseling: Professional guidance on genetic testing and interpretation of results.
- Oligonucleotide & Peptide Synthesis: Custom DNA/RNA oligonucleotides, peptides, and nucleotide modifications.
- Laboratory Solutions: Supplies the 4LAB automated pipetting workstation and other lab equipment via an e-shop.
Key Clients
Genomed serves a diverse clientele, including:
- Scientific institutes & universities
- Hospitals & healthcare networks
- Biotechnological & pharmaceutical companies
- Individual customers
Founded: 2007
Headquarters: Warsaw, Poland
Frequently Asked Questions
-
What is Genomed Spólka Akcyjna's (WSE-GEN) current market cap?As of 08/31/2026, Genomed Spólka Akcyjna (including the parent company, if applicable) has an estimated market capitalization of $10.57 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genomed Spólka Akcyjna (WSE-GEN) rank globally by market cap?Genomed Spólka Akcyjna global market capitalization ranking is approximately 42238 as of 08/31/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.